Hangzhou Alltest Biotech Co., Ltd. (SHA:688606)
China · Delayed Price · Currency is CNY 68.28
-0.95 (-1.37%)
Feb 13, 2026, 3:00 PM CST
Hangzhou Alltest Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 877.42 | 862.37 | 752.26 | 3,387 | 1,873 | 1,135 |
Other Revenue | 4.22 | 4.22 | 2.44 | 1.47 | 0.86 | 0.54 |
| 881.63 | 866.58 | 754.7 | 3,389 | 1,873 | 1,136 | |
Revenue Growth (YoY) | 8.47% | 14.82% | -77.73% | 80.88% | 64.98% | 370.53% |
Cost of Revenue | 396.6 | 392.82 | 380.66 | 1,563 | 843.87 | 204.18 |
Gross Profit | 485.04 | 473.77 | 374.04 | 1,826 | 1,030 | 931.37 |
Selling, General & Admin | 146.91 | 120.23 | 135.87 | 228.4 | 82.48 | 58.08 |
Research & Development | 98.54 | 95.82 | 121.17 | 207.3 | 95.46 | 55.11 |
Other Operating Expenses | 3.52 | 9.24 | 6.66 | 27.55 | 9.87 | 10.59 |
Operating Expenses | 250.15 | 233.17 | 275.02 | 471.08 | 191.89 | 128.28 |
Operating Income | 234.89 | 240.6 | 99.01 | 1,354 | 837.67 | 803.09 |
Interest Expense | -0.27 | -0.42 | -1.46 | -2.17 | -0.67 | - |
Interest & Investment Income | 43.05 | 45.66 | 54.2 | 67 | 44.86 | 6.13 |
Currency Exchange Gain (Loss) | 5.85 | 5.85 | 15.85 | 31.74 | -18.28 | -18.7 |
Other Non Operating Income (Expenses) | 2.03 | -1.4 | -1.33 | 0.73 | -3.95 | -0.9 |
EBT Excluding Unusual Items | 285.54 | 290.3 | 166.28 | 1,452 | 859.63 | 789.62 |
Impairment of Goodwill | - | - | - | -14.01 | - | - |
Gain (Loss) on Sale of Investments | 31.96 | 35.55 | 32.67 | -15.22 | 21.33 | - |
Gain (Loss) on Sale of Assets | -1.65 | 1.22 | -0.66 | 0.52 | -0.08 | -0.04 |
Asset Writedown | 6.71 | - | -0.28 | -60.7 | - | - |
Other Unusual Items | 20.08 | 20.65 | -0.57 | 19.11 | 14.65 | 2.08 |
Pretax Income | 342.64 | 347.71 | 197.44 | 1,381 | 895.53 | 791.67 |
Income Tax Expense | 47.55 | 44.8 | 17.16 | 195.99 | 129.84 | 112.44 |
Earnings From Continuing Operations | 295.09 | 302.91 | 180.28 | 1,185 | 765.69 | 679.23 |
Minority Interest in Earnings | -0.33 | -0.44 | 0.3 | -0.54 | - | - |
Net Income | 294.76 | 302.47 | 180.58 | 1,185 | 765.69 | 679.23 |
Net Income to Common | 294.76 | 302.47 | 180.58 | 1,185 | 765.69 | 679.23 |
Net Income Growth | 6.59% | 67.50% | -84.76% | 54.75% | 12.73% | 766.15% |
Shares Outstanding (Basic) | 79 | 79 | 79 | 79 | 75 | 60 |
Shares Outstanding (Diluted) | 79 | 79 | 79 | 79 | 75 | 60 |
Shares Change (YoY) | 0.08% | -0.02% | -0.07% | 5.96% | 25.16% | -0.10% |
EPS (Basic) | 3.72 | 3.82 | 2.28 | 14.95 | 10.24 | 11.36 |
EPS (Diluted) | 3.72 | 3.82 | 2.28 | 14.95 | 10.24 | 11.36 |
EPS Growth | 6.50% | 67.54% | -84.75% | 46.05% | -9.93% | 767.02% |
Free Cash Flow | 50.33 | 108.87 | -508.73 | 1,090 | 783.75 | 585.61 |
Free Cash Flow Per Share | 0.64 | 1.38 | -6.42 | 13.76 | 10.48 | 9.80 |
Dividend Per Share | 2.500 | 3.000 | 1.500 | 6.757 | 2.703 | 1.351 |
Dividend Growth | -16.67% | 100.00% | -77.80% | 150.00% | 99.99% | - |
Gross Margin | 55.02% | 54.67% | 49.56% | 53.87% | 54.96% | 82.02% |
Operating Margin | 26.64% | 27.76% | 13.12% | 39.97% | 44.71% | 70.72% |
Profit Margin | 33.43% | 34.90% | 23.93% | 34.97% | 40.87% | 59.81% |
Free Cash Flow Margin | 5.71% | 12.56% | -67.41% | 32.18% | 41.84% | 51.57% |
EBITDA | 264.23 | 266.44 | 120.18 | 1,378 | 846.45 | 807.12 |
EBITDA Margin | 29.97% | 30.75% | 15.92% | 40.65% | 45.18% | 71.08% |
D&A For EBITDA | 29.34 | 25.84 | 21.17 | 23.11 | 8.78 | 4.03 |
EBIT | 234.89 | 240.6 | 99.01 | 1,354 | 837.67 | 803.09 |
EBIT Margin | 26.64% | 27.76% | 13.12% | 39.97% | 44.71% | 70.72% |
Effective Tax Rate | 13.88% | 12.88% | 8.69% | 14.19% | 14.50% | 14.20% |
Revenue as Reported | 881.63 | 866.58 | 754.7 | 3,389 | 1,873 | 1,136 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.